Literature DB >> 35352060

Untangling the threads of immunotherapy research.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35352060     DOI： 10.1038/s43018-022-00367-0

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  7 in total

1.  Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.

Authors:  Ran Salomon; Hagar Rotem; Yonatan Katzenelenbogen; Assaf Weiner; Noy Cohen Saban; Tali Feferman; Ido Amit; Rony Dahan
Journal:  Nat Cancer       Date:  2022-02-21

2.  A decade of CAR T cell evolution.

Authors:  Marcela V Maus
Journal:  Nat Cancer       Date:  2022-03

3.  LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.

Authors:  Iván Pérez-Núñez; Catalina Rozalén; José Ángel Palomeque; Irene Sangrador; Mariona Dalmau; Laura Comerma; Anna Hernández-Prat; David Casadevall; Silvia Menendez; Daniel Dan Liu; Minhong Shen; Jordi Berenguer; Irene Rius Ruiz; Raul Peña; José Carlos Montañés; M Mar Albà; Sarah Bonnin; Julia Ponomarenko; Roger R Gomis; Juan Miguel Cejalvo; Sonia Servitja; Diego M Marzese; Lluis Morey; Leonie Voorwerk; Joaquín Arribas; Begoña Bermejo; Marleen Kok; Lajos Pusztai; Yibin Kang; Joan Albanell; Toni Celià-Terrassa
Journal:  Nat Cancer       Date:  2022-03-17

4.  The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response.

Authors:  Merav Cohen; Amir Giladi; Oren Barboy; Amos Tanay; Miriam Merad; Ido Amit; Pauline Hamon; Baoguo Li; Mor Zada; Anna Gurevich-Shapiro; Cristian Gabriel Beccaria; Eyal David; Barbara B Maier; Mark Buckup; Iris Kamer; Aleksandra Deczkowska; Jessica Le Berichel; Jair Bar; Matteo Iannacone
Journal:  Nat Cancer       Date:  2022-03-03

5.  Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.

Authors:  Zijie Feng; Xin He; Xuyao Zhang; Yuan Wu; Bowen Xing; Alison Knowles; Qiaonan Shan; Samuel Miller; Taylor Hojnacki; Jian Ma; Bryson W Katona; Terence P F Gade; Jörg Schrader; David C Metz; Carl H June; Xianxin Hua
Journal:  Nat Cancer       Date:  2022-03-21

6.  Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment.

Authors:  Chiara Falcomatà; Stefanie Bärthel; Sebastian A Widholz; Christian Schneeweis; Juan José Montero; Albulena Toska; Jonas Mir; Thorsten Kaltenbacher; Jeannine Heetmeyer; Jonathan J Swietlik; Jing-Yuan Cheng; Bianca Teodorescu; Oliver Reichert; Constantin Schmitt; Kathrin Grabichler; Andrea Coluccio; Fabio Boniolo; Christian Veltkamp; Magdalena Zukowska; Angelica Arenas Vargas; Woo Hyun Paik; Moritz Jesinghaus; Katja Steiger; Roman Maresch; Rupert Öllinger; Tim Ammon; Olga Baranov; Maria S Robles; Julia Rechenberger; Bernhard Kuster; Felix Meissner; Maximilian Reichert; Michael Flossdorf; Roland Rad; Marc Schmidt-Supprian; Günter Schneider; Dieter Saur
Journal:  Nat Cancer       Date:  2022-01-31

7.  An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Authors:  Sarah Chan; Nicole Belmar; Sun Ho; Bryan Rogers; Marcia Stickler; Michelle Graham; Eileen Lee; Ninian Tran; Dong Zhang; Priyanka Gupta; Mien Sho; Tracy MacDonough; Andrew Woolley; Han Kim; Hong Zhang; Wei Liu; Pingping Zheng; Zoltan Dezso; Kyle Halliwill; Michele Ceccarelli; Susan Rhodes; Archana Thakur; Charles M Forsyth; Mengli Xiong; Siu Sze Tan; Ramesh Iyer; Marc Lake; Enrico Digiammarino; Li Zhou; Lance Bigelow; Kenton Longenecker; Russell A Judge; Cassie Liu; Max Trumble; Jonathan P Remis; Melvin Fox; Belinda Cairns; Yoshiko Akamatsu; Diane Hollenbaugh; Fiona Harding; Hamsell M Alvarez
Journal:  Nat Cancer       Date:  2022-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.